Canadian speciality pharmaceutical company Paladin Labs has completed the acquisition of all outstanding common shares of Labopharm.
Labopharm develops novel polymeric, nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs.
Paladin Labs interim president and CEO Mark Beaudet said that, through the addition of established international revenue streams, the acquisition will provide them the opportunity to build upon their existing operational capabilities.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Clinical Trials Arena Excellence Awards - Have you nominated?
Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!
Nominate Now
